Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
October 05 2020 - 7:00AM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, today announced a presentation at the Chardan Virtual
4th Annual Genetic Medicines Conference on Monday, October 5,
2020.
Date: Monday, October 5, 2020
Time: 11:00 – 11:25 AM Eastern Time
Location: Virtual Webcast
The presentation will be available for live streaming via
https://wsw.com/webcast/chard6/xcur/1881648.
Replays of the webcast will be available on Exicure’s website
for 30 days following the webcast.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is based in Chicago, IL and has an office in Cambridge,
MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201005005240/en/
Media Contact: MacDougall Karen Sharma 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024